The World Health Organization (WHO) has recently declared COVID-19 a pandemic.
On March 11, 2020 the World Health Organization characterized the novel coronavirus, termed coronavirus disease 2019 (COVID-19), a pandemic. This announcement followed the rapid worldwide rise of infected individuals after the initial identification of pneumonia associated with an unknown virus in China in December 2019, later determined to be caused by infection with COVID-19.
Coronaviruses (CoV) are a large family of viruses that historically have been associated with illness ranging from mild symptoms similar to the common cold to more severe respiratory disease. Infection with the novel COVID-19 has been associated with a wide range of responses, from no symptoms to more severe disease that has included pneumonia, severe acute respiratory syndrome, kidney failure, and death. The incubation period for COVID-19 is believed to be within 14 days after exposure, with most illness occurring within about 5 days after exposure. The ability of someone with no symptoms to transmit infection to another person has heightened the public health challenge of COVID-19.
There is currently no treatment recommended for COVID-19 infection or shown to be effective against other coronaviruses. We are aggressively pursuing the development of novel antiviral compounds for the treatment of coronavirus infections using our established proprietary drug discovery platform. By targeting the viral replication enzymes and protease, we believe it is possible to develop an effective treatment for all coronaviruses including COVID-19, Severe Acute Respiratory Syndrome (SARS), and Middle East Respiratory Syndrome (MERS) - coronaviruses.
To learn more about coronavirus, please visit the information page at the Center for Disease Control and Prevention (CDC).